Get the Stockscreener App
15.52
22.90%
-4.61
After Hours:
14.90
-0.62
-3.99%
Edgewise Therapeutics Inc stock is traded at $15.52, with a volume of 16.11M.
It is down -22.90% in the last 24 hours and down -40.70% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$20.13
Open:
$14.5
24h Volume:
16.11M
Relative Volume:
12.03
Market Cap:
$1.92B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-10.03
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
-30.28%
1M Performance:
-40.70%
6M Performance:
-43.07%
1Y Performance:
-12.17%
1-Day Range:
$12.18
$16.13
1-Week Range:
$12.18
$25.36
52-Week Range:
$12.18
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
15.52 | 1.92B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos - insights.citeline.com
Edgewise Therapeutics selling $200M in stock to support drug commercialization - BizWest
Edgewise down on atrial fibrillation; cardiomyopathy data positive - BioWorld MedTech
Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On (EWTX) - Seeking Alpha
American Century Companies Inc. Sells 164,034 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Why These Two Biotech Stocks Just Diverged - Investor's Business Daily
Edgewise Therapeutics sets $20.13 share price in $200 million stock offering By Investing.com - Investing.com South Africa
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia
CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus
Edgewise stock holds Buy rating, $50 target from Truist Securities By Investing.com - Investing.com UK
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study - Benzinga
Why Edgewise Therapeutics (EWTX) Stock Is Falling - Benzinga
Edgewise falls on safety, efficacy doubts for heart disease drug - TradingView
Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha
Edgewise Therapeutics stock tumbles after trial results and stock offering By Investing.com - Investing.com Australia
Edgewise Therapeutics stock tumbles after trial results and stock offering - Investing.com India
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - BioSpace
Edgewise Therapeutics sets $20.13 share price in $200 million stock offering - Investing.com Australia
Edgewise Therapeutics Prices 9.9 Mln Offering At $20.13/shr; Stock Fell In Pre-market - Nasdaq
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 Cirrus-Hcm Four-Week Trial of Edg-7500 in Hypertrophic Cardiomyopathy - MarketScreener
Edgewise’s heart drug shows promise in Phase 2 trial - Endpoints News
Edgewise Therapeutics Reports New Results From Phase 2 Hypertrophic Cardiomyopathy Trial - MarketScreener
Edgewise reports promising HCM trial results for EDG-7500 - Investing.com India
Edgewise Therapeutics Prices $200 Million Offering - MarketScreener
Edgewise Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Edgewise Therapeutics announces top-line data of EDG-7500 from CIRRUS-HCM trial - TipRanks
Why Edgewise Therapeutics Is Rising In Pre-market? - Nasdaq
$200M Funding Positions Edgewise to Launch Breakthrough Muscular Dystrophy Treatment - Stock Titan
Edgewise Therapeutics Announces Positive Top-Line Results From Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy - MarketScreener
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – Company Announcement - Financial Times
Teacher Retirement System of Texas Buys 1,772 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Artisan Partners Limited Partnership Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Hypertrophic Cardiomyopathy Market to Show Remarkable Growth - openPR.com
Quantbot Technologies LP Invests $103,000 in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by American Century Companies Inc. - Defense World
EFG Asset Management North America Corp. Acquires New Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $45.38 Consensus Target Price from Brokerages - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 9.3%Here's Why - MarketBeat
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Benzinga
Intech Investment Management LLC Boosts Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Major Phase 2 Trial Results: Edgewise's New HCM Drug Could Transform Patient Care - Stock Titan
EDG-4131 active in model of Becker muscular dystrophy - BioWorld MedTech
Victory Capital Management Inc. Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Charles Schwab Investment Management Inc. Has $14.35 Million Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.5%Should You Sell? - MarketBeat
Truist maintains Buy rating on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownShould You Sell? - MarketBeat
(EWTX) Technical Data - news.stocktradersdaily.com
Amundi Buys 191,267 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.3%Here's What Happened - MarketBeat
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):